Advanced liver disease: What every hepatitis C virus treater should know

Topics in Antiviral Medicine

Volumn 19, Issue 3, 2011, Pages 121-125

  Sherman, Kenneth E ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOPSY; CASE REPORT; DISEASE COURSE; HEPATITIS C; HEPATITIS C VIRUS; HOSPITALIZATION; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FAILURE; LIVER TUMOR; MALE; MIDDLE AGED; PATHOGENICITY; PATHOLOGY; REVIEW; VIROLOGY;

BIOPSY; CARCINOMA, HEPATOCELLULAR; DISEASE PROGRESSION; HEPACIVIRUS; HEPATITIS C; HUMANS; LIVER CIRRHOSIS; LIVER FAILURE; LIVER NEOPLASMS; MALE; MIDDLE AGED; SEVERITY OF ILLNESS INDEX;

EID: 84856036274     PISSN: 21615861     EISSN: 21615853     Source Type: Journal    
DOI: None     Document Type: Article

References (4)

1. Afdhal NH. The natural history of hepatitis C. Semin Liver Dis. 2004;24(Suppl 2): 3-8.
2. Sort P, Navasa M, Arroyo V, et al. Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis. N Engl J Med. 1999;341:403-409.
3. Rolachon A, Cordier L, Bacq Y, et al. Ciprofloxacin and long-term prevention of spontaneous bacterial peritonitis: results of a prospective controlled trial. Hepatology. 1995;22:1171-1174.
4. Bass NM, Mullen KD, Sanyal A, et al. Rifaximin treatment in hepatic encephalopathy. N Engl J Med. 2010;362:1071-1081.